+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Disease-Modifying Treatment in Progressive Multiple Sclerosis



Disease-Modifying Treatment in Progressive Multiple Sclerosis



Current Treatment Options in Neurology 20(5): 12



Multiple sclerosis (MS) is an immune-mediated disorder that affects the central nervous system (CNS), often first affecting people in early adulthood. Although most MS patients have a relapsing-remitting course (RRMS) at disease onset, a substantial proportion later develop chronic progression, termed secondary progressive MS (SPMS). Approximately 10% of MS patients experience chronic progression from disease onset, termed primary progressive multiple sclerosis (PPMS). Although several disease-modifying treatment (DMT) options exist for relapsing forms of this disease, DMT options are few for progressive MS (PPMS and SPMS). Herein, we strive to define progressive MS, review major clinical trials aimed at progressive MS, and delineate potential strategies in the management of progressive MS. In 2017, the first DMT for PPMS, the B lymphocyte-depleting monoclonal antibody, ocrelizumab, came to market. Ocrelizumab reduced 12-week confirmed disability progression (CDP) by 24% versus placebo. Siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month CDP by 21% versus placebo in SPMS. Ibudilast slowed brain atrophy in PPMS and SPMS patients in a multicenter phase 2b study. Smaller early phase studies of alpha-lipoic acid and simvastatin each found slowing of rate of whole brain atrophy in SPMS patients. Reasons now exist for optimism in the search for DMTs for progressive MS. It remains a challenge to identify outcome measures that accurately reflect the underlying pathology in progressive MS, which is less inflammatory and more degenerative than RRMS.

(PDF emailed within 0-6 h: $19.90)

Accession: 058427311

Download citation: RISBibTeXText

PMID: 29627873

DOI: 10.1007/s11940-018-0496-3


Related references

Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. European Journal of Neurology 2018, 2018

Disease-modifying treatments for progressive multiple sclerosis. Multiple Sclerosis 19(11): 1428-1436, 2014

New Advances in Disease-Modifying Therapies for Relapsing and Progressive Forms of Multiple Sclerosis. Neurologic Clinics 36(1): 173-183, 2018

Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?. Multiple Sclerosis 15(12): 1528-1531, 2010

Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment. Patient Preference and Adherence 10: 659-667, 2016

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA 321(2): 175-187, 2019

Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis. Cns Drugs 32(12): 1145-1157, 2018

Access to and Use of Clinical Services and Disease-Modifying Therapies by People with Progressive Multiple Sclerosis in the United Kingdom. International Journal of Ms Care 19(6): 275-282, 2017

Symptomatic and disease-modifying therapies for multiple sclerosis: recent developments: highlights of the 9th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis, October 3, 2004, Toronto, Ontario, Canada. Reviews in Neurological Diseases 2(1): 23-26, 2006

A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives. International Journal of Molecular Sciences 17(10), 2016

A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis. Journal of Clinical Medicine Research 10(2): 88-105, 2018

Disease-modifying agents in progressive multiple sclerosis: management of 100 patients at Louis Stokes Cleveland VAMC, Spinal Cord Injury Division. Journal of Rehabilitation Research and Development 48(10): 1223-1230, 2012

To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question. Expert Review of Neurotherapeutics 17(9): 847-849, 2017

Disease modifying treatment in multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry 71 Suppl 2: Ii20-Ii21, 2001

Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone Response to therapy is linked to duration of progressive disease. Neurology 50(4 SUPPL 4): A146, April, 1998